secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000950170-22-007845
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance
-----------------------------------------------------------------

- Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).
- Net loss $17.6M ($0.64/share); adjusted net loss $14.9M ($0.54/share).
- 2022 revenue guidance raised to $41.5-45.5M from $40-44M, implying 84-101% annual growth.
- Amended Oxford Finance loan: extends draw periods for remaining $20M, interest-only period to 2025.
- Procedure volumes: 4,166 LALs sold (+166% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/0000950170-22-007845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/rxst-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer